Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 3, 2015, Pages 608-619

  Huang, Shuai ^a   Zou, Xiao ^a   Zhu, Jie Ning ^a   Fu, Yong Heng ^a   Lin, Qiu Xiong ^a   Liang, Ye You ^a,b   Deng, Chun Yu ^a   Kuang, Su Juan ^a   Zhang, Meng Zhen ^a   Liao, Yu Lin ^b   Zheng, Xi Long ^c   Yu, Xi Yong ^a   Shan, Zhi Xin ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

Cardiac hypertrophy; Cardiomyocyte; Cyclin; MicroRNA 16; Retinoblastoma protein

Indexed keywords

ANIMALIA; MUS; RATTUS;

CCND1 PROTEIN, RAT; CCND2 PROTEIN, RAT; CYCLIN D1; CYCLIN D2; CYCLIN E1, RAT; CYCLINE; MICRORNA; MIRN16 MICRORNA, RAT; MYC PROTEIN; PHENYLEPHRINE; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; STAT3 PROTEIN, RAT;

ABDOMINAL AORTA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL LINE; DISEASE MODEL; ENZYME ACTIVATION; GENETICS; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; SURGERY;

ANIMALS; AORTA, ABDOMINAL; CARDIOMEGALY; CELL LINE; CYCLIN D1; CYCLIN D2; CYCLINS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MYOCYTES, CARDIAC; PHENYLEPHRINE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RATS, SPRAGUE-DAWLEY; RETINOBLASTOMA PROTEIN; STAT3 TRANSCRIPTION FACTOR;

EID: 84923391799     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12445     Document Type: Article

References (43)

1. Chien KR, Grace AA, Hunter JJ. Molecular and cellular biology of cardiac hypertrophy and failure. In: Chien KR, editor. Molecular basis of cardiovascular disease. Philadelphia, PA: Saunders; 1999. pp. 211-50.
2. Perrino C, Naga Prasad SV, Mao L, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006; 116: 1547-60.
3. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013; 123: 37-45.
4. Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 1997; 80: 228-41.
5. Poolman RA, Brooks G. Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. J Mol Cell Cardiol. 1998; 30: 2121-35.
6. Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol. 1998; (3 Pt 2): H814-22.
7. Nozato T, Ito H, Tamamori M, et al. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Jpn Circ J. 2000; 64: 595-601.
8. Busk PK, Bartkova J, Strøm CC, et al. Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res. 2002; 56: 64-75.
9. Hinrichsen R, Hansen AH, Haunsø S, et al. Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy. Cell Prolif. 2008; 41: 813-29.
10. Hotchkiss A, Robinson J, MacLean J, et al. Role of D-type cyclins in heart development and disease. Can J Physiol Pharmacol. 2012; 90: 1197-207.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
12. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613-8.
13. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009; 119: 2772-86.
14. Li Q, Song XW, Zou J, et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci. 2010; 123: 2444-52.
15. Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res. 2012; 93: 563-72.
16. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012; 3: 1078.
17. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013; 127: 2097-106.
18. Heymans S, Corsten MF, Verhesen W, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013; 128: 1420-32.
19. Huang ZP, Chen J, Seok HY, et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res. 2013; 112: 1234-43.
20. Phrommintikul A, Tran L, Kompa A, et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2008; 294: H1804-14.
21. Rockman HA, Ono S, Ross RS, et al. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA. 1994; 91: 2694-8.
22. Slawson SE, Roman BB, Williams DS, et al. Cardiac MRI of the normal and hypertrophied mouse heart. Magn Reson Med. 1998; 39: 980-7.
23. Communal C, Singh K, Pimentel D, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998; 98: 1329-34.
24. Zhu JN, Chen R, Fu YH, et al. Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. PLoS ONE. 2013; 8: e75557.
25. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.
26. Shan ZX, Lin QX, Deng CY, et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 2010; 584: 3592-600.
27. Rivas MA, Venturutti L, Huang YW, et al. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res. 2012; 14: R77.
28. Busk PK, Hinrichsen R. Cyclin D in left ventricle hypertrophy. Cell Cycle. 2003; 2: 91-5.
29. Vara D, Bicknell KA, Coxon CH, et al. Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy. J Biol Chem. 2003; 278: 21388-94.
30. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009; 104: 170-8.
31. Linsley PS, Schelter J, Burchard J, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycleprogression. Mol Cell Biol. 2007; 27: 2240-52.
32. Liu Q, Fu H, Sun F, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008; 36: 5391-404.
33. Aranha MM, Santos DM, Xavier JM, et al. Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation. BMC Genomics. 2010; 11: 514.
34. Liu JL, Jiang L, Lin QX, et al. MicroRNA 16 enhances differentiation of human bone marrow mesenchymal stem cells in a cardiac niche toward myogenic phenotypes in vitro. Life Sci. 2012; 90: 1020-6.
35. Cui X, Witalison EE, Chumanevich AP, et al. The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS ONE. 2013; 8: e53791.
36. Hannan RD, Stefanovsky V, Taylor L, et al. Overexpression of the transcription factor UBF1 is sufficient to increase ribosomal DNA transcription in neonatal cardiomyocytes: implications for cardiac hypertrophy. Proc Natl Acad Sci USA. 1996; 93: 8750-5.
37. Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010; 128: 191-227.
38. Tamamori M, Ito H, Hiroe M, et al. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol. 1998; 275: H2036-40.
39. Nozato T, Ito H, Watanabe M, et al. Overexpression of cdk inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J Mol Cell Cardiol. 2001; 33: 1493-504.
40. Frias MA, Rebsamen MC, Gerber-Wicht C, et al. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy. Cardiovasc Res. 2008; 73: 57-65.
41. Willey CD, Palanisamy AP, Johnston RK, et al. STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci. 2008; 4: 184-99.
42. Li Y, Zhang H, Liao W, et al. Transactivated EGFR mediates α1-AR-induced STAT3 activation and cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2011; 301: H1941-51.
43. Leifheit-Nestler M, Wagner NM, Gogiraju R, et al. Importance of leptin signaling and signal transducer and activator of transcription-3activation in mediating the cardiac hypertrophy associated with obesity. J Transl Med. 2013; 11: 170.